Medpace (NASDAQ:MEDP) Shares Gap Down – What’s Next?

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) gapped down prior to trading on Thursday . The stock had previously closed at $508.46, but opened at $375.15. Medpace shares last traded at $383.9190, with a volume of 311,510 shares changing hands.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 beat: Medpace reported Q1 GAAP EPS of $4.28 and revenue of $706.6M, both above Street estimates, with 26.5% YoY revenue growth and a sizable backlog. Medpace Q1 Results
• Neutral Sentiment: Company maintained FY‑2026 guidance (EPS range $16.68–$17.50; revenue roughly $2.8B–$2.9B), which keeps management’s view intact but leaves EPS midpoint slightly under some analyst consensus. Guidance & Call
• Negative Sentiment: Bookings miss / book‑to‑bill <1: Net new business awards produced a Q1 book‑to‑bill of ~0.88, signaling bookings lag revenue and raising near‑term demand concerns that weighed heavily on the stock. Book-to-bill Coverage
• Negative Sentiment: Leadership change disclosed: President Jesse Geiger plans to retire (effective May 31) and the CEO will reassume the president role temporarily — a near‑term governance/turnover risk cited by market participants. Leadership Disclosure
• Negative Sentiment: Class‑action activity: Multiple law firms and plaintiff notices were announced this week alleging investors were misled about growth — increased legal risk and potential distraction for management. Class Action Notices

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MEDP shares. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a report on Tuesday, February 10th. Leerink Partners decreased their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and decreased their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Finally, Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $486.67.

Medpace Stock Performance

The stock has a market capitalization of $11.43 billion, a P/E ratio of 26.08, a price-to-earnings-growth ratio of 2.43 and a beta of 1.39. The stock’s fifty day simple moving average is $471.41 and its two-hundred day simple moving average is $537.55.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same period in the previous year, the firm posted $3.67 EPS. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Medpace

Institutional investors have recently added to or reduced their stakes in the business. Quent Capital LLC bought a new stake in Medpace during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. bought a new stake in Medpace during the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. grew its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace during the 4th quarter worth approximately $30,000. Finally, Elyxium Wealth LLC acquired a new position in shares of Medpace in the 4th quarter worth approximately $30,000. 77.98% of the stock is owned by institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.